CUE Cue Biopharma, Inc.
Financings ·
Cue will sell 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for gross proceeds of about $50.0 million. Cormorant Asset Management led. The 8-K also reports RSU grants to officers and directors.
Cue Biopharma is selling 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for about $50.0 million in gross proceeds. Its release says the lead candidate is advancing toward Phase 1, while its annual report calls that candidate preclinical.
Cue Biopharma agreed to pay a $15.0 million upfront for rights to Ascendant-221, an anti-IgE antibody still in a Phase 2 study run by the licensor's affiliate, and to issue pre-funded warrants for up to 551,724 shares. Milestones could reach $676.5 million, and the company's own release cites a current going concern determination.
Cue Biopharma's 1-for-30 reverse split takes effect at 5:00 p.m. Eastern Time on April 23, 2026. The company says it is meant to restore compliance with Nasdaq's minimum bid price, and its filing still carries a going-concern determination.
Cue Biopharma holders approved a reverse split at a ratio between 1-for-30 and 1-for-50. The board will pick the ratio and the timing without another stockholder vote, and the filing does not say why the split is wanted.
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable therapeutics that selectively engage and modulate disease-specific T cells for autoimmune and inflammatory diseases. Its Immuno-STAT platform is designed to modulate disease-relevant T cells, and the company describes it as flexible and modular. Its lead candidate, CUE-401, is a preclinical bifunctional fusion protein that combines engineered variants of TGF-beta and IL-2 to induce regulatory T cells and reduce pro-inflammatory autoreactive cells. The company is preparing to file an investigational new drug application in the second quarter of 2026 and anticipates receiving human safety data starting in the second half of 2026. The CUE-500 series redirects anti-viral memory T cells to deplete pathogenic cells, and CUE-501 is licensed to Boehringer Ingelheim International GmbH for autoimmune B cell depletion. In oncology, CUE-101 and CUE-102 have been licensed to ImmunoScape Pte. Ltd., which is developing a Seed-and-Boost immunotherapy that combines them with its tumor-specific T cell receptors.
| Product or program | What it is | Stage |
|---|---|---|
| CUE-401 | Bifunctional TGF-beta and IL-2 fusion protein for autoimmune diseases | preclinical; IND filing being prepared for the second quarter of 2026 |
| CUE-501 | Redirects anti-viral T cells to deplete autoreactive B cells | |
| CUE-101 and CUE-102 | T cell activators for HPV+ cancers and WT1-expressing cancers | licensed to ImmunoScape Pte. Ltd. for oncology |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $27.5 million | $9.3 million |
| Research and development | $37.7 million | $36.3 million |
| Net income (loss) | -$26.6 million | -$40.7 million |
| Cash from operations | -$21.7 million | -$36.3 million |
| Cash and equivalents | $27.1 million | $22.5 million |
| Short-term investments | $0 |
Our latest story on this, dated Apr 22, 2026: "Cue Biopharma sets 1-for-30 reverse stock split for April 23, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 1, 2026: "Cue Biopharma licenses Ascendant-221 from Ascendant Health, to pay $15.0 million upfront". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 10, 2026: "Cue Biopharma agrees to $50.0 million private placement led by Cormorant". The story links the filing or release it is based on. Read the story.
Cue Biopharma, Inc. trades under the ticker CUE on NASDAQ.
Cue Biopharma, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1UC0; LSX:A426PN.
The SEC Central Index Key (CIK) for Cue Biopharma, Inc. is 1645460. Its filings are on SEC EDGAR.
7,264,414 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Cue Biopharma, Inc. under United States.
Our directory classifies Cue Biopharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cue Biopharma, Inc. is US22978P2056.
aibio.space lists Cue Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable therapeutics that selectively engage and modulate disease-specific T cells for autoimmune and inflammatory diseases. Its Immuno-STAT platform is designed to modulate disease-relevant T cells, and the company describes it as flexible and modular.
CUE-401: Bifunctional TGF-beta and IL-2 fusion protein for autoimmune diseases Stage: preclinical; IND filing being prepared for the second quarter of 2026.
CUE-501: Redirects anti-viral T cells to deplete autoreactive B cells Stage: licensed to Boehringer Ingelheim International GmbH; stage not stated.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio